Condition: Patients With Mild or Moderate Hepatic Impairment · Sponsor: Taisho Pharmaceutical Co., Ltd.
An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment
This description comes directly from the study's public registry record.
Taisho Pharmaceutical Co., Ltd. · 81-3-3985-1118 · shu_chiken@taisho.co.jp
Always discuss trial participation with your own doctor first.
| Taisho Pharmaceutical Co., Ltd selected site | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07231029